Immunomodulatory and pharmacologic properties of imiquimod.
about
Imiquimod - Its role in the treatment of cutaneous malignanciesDelivery of host cell-directed therapeutics for intracellular pathogen clearanceImiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.Involution of infantile haemangiomas after imiquimod 5% cream.Pilot study examining the combined use of pulsed dye laser and topical Imiquimod versus laser alone for treatment of port wine stain birthmarks.Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature.Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustardUse of topical imiquimod in the treatment of VIN: a case report and review of the literature.Kaposi's sarcoma responding to topical imiquimod 5% cream: a case report.Non-surgical treatments of primary, non-melanoma eyelid malignancies: a review.Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.Fighting infection using immunomodulatory agents.Experience in treating molluscum contagiosum in children with imiquimod 5% cream.Immunotherapy for nonmelanoma skin cancer: does it have a future?Imiquimod: a potential role in dermatology?Efficacy of an immune modulator in experimental Chlamydia trachomatis infection of the female genital tract.Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination.Immunomodulator-based enhancement of anti smallpox immune responses.Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infectionBowen's Disease Treated with Imiquimod and CryotherapyUse of topical immunomodulators in organ transplant recipients.Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna.Management of Extramammary Paget's Disease: A Case Report and Review of the Literature.The use of imiquimod in the treatment of periocular tumours.Novel findings in drug-induced dendritic cell tolerogenicity.Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.Acute renal failure caused by imiquimod 5% cream in a renal transplant patient: review of the literature on side effects of imiquimod.An update on nonmelanoma skin cancer.Systematic identification of small molecule adjuvants.Oculoplastic aspects of ocular oncology.Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategiesLmax and imiquimod 3.75%: the new standard in AK management.Treatment of Porokeratosis: A Systematic Review.Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod.Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study.The effect of 5-amino-3-methyl-4-isoxazolecarboxylic acid hydrazide on lymphocyte subsets and humoral immune response in SRBC-immunized mice.Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod.Acantholytic pityriasis rubra pilaris associated with imiquimod 3.75% application.Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial.Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream.
P2860
Q26796536-DE7F485D-DCB1-41AD-A78D-80AF1D3362DBQ27006858-14533DA9-BC40-41D7-8E00-F7C92E8BBA5FQ33293591-A9F068B4-30A9-4139-A8A1-7C77DCEE6EB7Q33335289-A323E6CC-E001-4B85-BF87-26F4013339BEQ33379390-8A43BBCB-52BC-4C38-93D7-5674C6DE1334Q33444923-5D66C4B3-6B3F-4364-9C59-CE0721043F7FQ33590400-6EBAA566-865E-4E31-BD78-4D41DBDCFDE0Q33623698-4F46C59D-6CF2-4B6E-B7C3-049E4B6F3D2CQ33681669-DD9ECB5C-AA82-4E24-8EE5-2CE24059673EQ33735219-A4552601-B194-4429-8E55-63E8A4792B3FQ34020057-803DA133-2B54-4C30-AA84-82A81908B04AQ34103603-AA2C8EE5-488A-4FC8-BA6E-2DC06AB4F4CBQ34276705-37E5FC37-9CB2-404C-874E-FCC0C33E14BEQ34568136-9A278560-BC2F-4E47-B00A-C9F4BB3798EFQ34722728-DF54080D-EE48-4AD5-A64C-B9F9A1275000Q35056798-0038E3E1-8357-4F87-B68F-A4EBB0C85D31Q35132732-F6B231E7-1852-4DC6-B86F-01E1355473B5Q35391402-C0514AAA-3F1C-4EFD-8DD5-791AA0EAC03CQ35751196-60361EEF-AF9B-492F-8AD5-5FFD751D5D97Q36021174-0631D3AC-1BE9-42B4-9380-C412E4ACD7C4Q36103147-C53EDF33-E96B-4070-B575-0C61876117F7Q37138613-36E83413-CD0E-4698-A6E6-2BB8B9AC2898Q37358752-3074D3A8-7A6C-4CCD-AF12-B0946A3B9B9BQ37731551-B159EAF8-DBB7-4626-9969-2D32E9B4240EQ37809070-CB3DA5B1-FCD4-41AB-8684-709104010BAEQ37831354-3D54E3FF-8143-45A2-A7F6-3102DA799F81Q37838175-FD7FE833-A353-4918-9201-9C4287682DBAQ37851020-4BB5D20A-FA64-4529-BDFF-A93EDF6AFB9EQ38020881-635BA929-6187-4691-89CC-BB1AB4E980CDQ38063746-A6C78997-57EB-42C9-8B04-88D39AE78597Q38161363-5AABC197-BE7A-4C96-946D-FE27E0DD221AQ38282402-2E075F51-FA1A-4BE5-9181-D8F9C3C50191Q39173690-ADF903B1-5EEF-4521-93F2-1F776BBDA02DQ39557726-15833AA1-3893-40C1-89EE-8A50F76D17C2Q39761591-595A77DE-D66A-4729-BE55-DE2BC78C63E6Q41554945-D5878C6B-BF76-457E-B88D-4225A33A3D62Q42162407-0B21D3EA-12AB-403B-807B-224D773018DAQ42224681-A7742AEE-EE45-45A4-9E50-ED8EE91984A4Q44655061-360CBE31-A419-4A8E-A589-A855088C1C1FQ44655067-230C6E35-8E75-4662-8FC3-D8C9A806B022
P2860
Immunomodulatory and pharmacologic properties of imiquimod.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Immunomodulatory and pharmacologic properties of imiquimod.
@ast
Immunomodulatory and pharmacologic properties of imiquimod.
@en
type
label
Immunomodulatory and pharmacologic properties of imiquimod.
@ast
Immunomodulatory and pharmacologic properties of imiquimod.
@en
prefLabel
Immunomodulatory and pharmacologic properties of imiquimod.
@ast
Immunomodulatory and pharmacologic properties of imiquimod.
@en
P356
P1476
Immunomodulatory and pharmacologic properties of imiquimod.
@en
P2093
D N Sauder
P356
10.1067/MJD.2000.107808
P407
P433
P577
2000-07-01T00:00:00Z